Drugs / aCoV2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04806529 | Dec 2020 | influenza | Seqirus | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aCoV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04806529 ↗ |
| Known as | Adjuvanted SARS-CoV-2 Subunit vaccine | “Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)” NCT04806529 ↗ |
| Modality | Vaccine | “Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine” NCT04806529 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) into the deltoid muscle” NCT04806529 ↗ |